Pain medicine guide: types, effects and precautions
This article covers three common medicines—loxoprofen, ibuprofen and acetaminophen—and is not a complete list of pain medicines.
These are not three pain medicines of different strengths, but two different pharmacological pathways. Loxoprofen and ibuprofen are both nonselective NSAIDs. Their stronger peripheral anti-inflammatory action comes with prostaglandin-related costs to the gastrointestinal tract, kidneys, fluid balance and cardiovascular system. Acetaminophen acts mainly through central antipyretic and analgesic pathways, with weak anti-inflammatory activity; its central toxicological concern shifts to hepatic NAPQI.
1. Overview: see the whole system first
Key distinction: the therapeutic effects and organ adverse effects of NSAIDs arise from the same prostaglandin physiological system. Acetaminophen is not a weaker NSAID; it follows a different pharmacological pathway.
Loxoprofen
Core role: A prodrug of a nonselective NSAID. The parent drug itself has very weak COX inhibition and is converted after absorption into an active trans-OH metabolite.
Commonly prescribed in Japan; fewer large global outcome studies are available than for ibuprofen.
Ibuprofen
Core role: A nonselective NSAID. Most marketed products are R/S racemates. S(+)-ibuprofen is the main COX-inhibiting enantiomer, and some R is converted to S in the body.
One of the most widely used NSAIDs worldwide, with one of the most extensive RCT and meta-analysis evidence bases.
Acetaminophen
Core role: Central antipyretic and analgesic action. The precise mechanism remains incompletely understood; peripheral anti-inflammatory effects are weak.
It has fewer typical NSAID gastric and renal mechanisms, but hepatotoxicity in overdose or high-risk situations is the central safety concern.
2. COX / Prostaglandins: why NSAIDs are both effective and hazardous
Intuition: COX is not simply an inflammation enzyme. It also maintains normal gastric mucosa, renal blood flow and platelet/vascular physiology. Inhibiting this same pathway produces both therapeutic effects and class toxicity.
3. Three molecules, three different pharmacological profiles
3.1 Loxoprofen: it must first be converted to become active
Prodrug：After oral administration, the parent drug is rapidly absorbed and undergoes carbonyl reduction to form the active trans-OH metabolite. In vitro studies show little appreciable inhibition of human COX-1/2 by the parent drug, whereas the active metabolite inhibits COX nonselectively.
Clinical implication: Being a prodrug may reduce direct local gastric irritation from the unabsorbed parent drug, but does not eliminate ulcers / bleeding / AKI caused by systemic COX inhibition.
Mechanistic evidence3.2 Ibuprofen: chirality matters
Conventional ibuprofen is an R/S racemate. S(+)-ibuprofen is the main COX inhibitor. The R-enantiomer itself inhibits COX only weakly, but some R undergoes unidirectional chiral inversion to S in humans.
Clinical implication: The effect is not as simple as assuming that all 200 mg has the same activity. This is one reason milligram doses cannot be used to compare potency directly across molecules.
Stereochemical pharmacology3.3 Acetaminophen: the mechanism is not fully settled
The most defensible current description is that it acts mainly in the CNS to inhibit prostaglandin signaling involved in pain and thermoregulation. Serotonergic, endocannabinoid / AM404 and TRPV1 pathways all have experimental support.
Do not treat COX-3 as an established human clinical mechanism. Modern literature still considers the complete analgesic mechanism of acetaminophen unresolved.
Mechanism partly unresolved4. PK / PD: rapid absorption does not necessarily mean greater strength
| Item | Loxoprofen | Ibuprofen | Acetaminophen / Calonal |
|---|---|---|---|
| Pharmacological class | NSAID prodrug | NSAID racemate | Non-NSAID analgesic / antipyretic |
| Main active form | active trans-OH metabolite | Primarily S(+)-ibuprofen | Parent drug + downstream CNS metabolites / signaling |
| Common adult prescription references in Japan* | For general pain, usually 60 mg per dose, three times daily | For general inflammatory pain, commonly 600 mg/day in three divided doses; usually 200 mg as needed for URTI | For the adult analgesia indication in Japan: usually 300–1000 mg per dose at intervals of ≥4–6 h. The labeling limit for this indication is 4000 mg/day, not a general self-medication limit |
| Tmax(labeling studies) | Parent drug approximately 0.45 h; active trans-OH approximately 0.79 h | Japanese data for 200 mg: approximately 2.1 h; standard US tablets commonly 1–2 h | Calonal 400 mg, fasting: approximately 0.46 h |
| t½ (approximate) | parent 1.22 h；active trans-OH 1.31 h | Approximately 1.8–2.0 h | Calonal 400 mg: approximately 2.36 h |
| Anti-inflammatory action | Yes | Yes | Clinically weak |
| Main elimination route | Urinary excretion after metabolism; glucuronide conjugates | Hepatic metabolism (CYP2C9 is important) → renal excretion | Mainly glucuronidation / sulfation; a small fraction via CYP → NAPQI |
* These are reference ranges from current Japanese prescription labeling, not individual medication instructions. Dose varies with disease, country, age, formulation and comorbidities. For example, Japanese Calonal labeling for acute upper respiratory inflammation in adults separately specifies 300–500 mg per dose as needed, generally no more than twice daily, with a daily maximum of 1500 mg. The 4000 mg limit for the analgesia indication must not be applied here. Tmax values come from different studies and cannot be treated as a direct head-to-head comparison of onset.
5. Clinical effects: the pain phenotype matters more than the medicine’s name
Acute inflammatory dental pain: strong direct evidence for ibuprofen
Cochrane included 7 studies with 2241 participants. Most compared ibuprofen 400 mg vs acetaminophen 1000 mg; the RR for achieving at least 50% pain relief over 6 hours was 1.47（95% CI 1.28–1.69）, supporting greater effectiveness of ibuprofen in the highly inflammatory model of wisdom-tooth extraction.
This conclusion applies to a specific dose and pain model; it does not mean ibuprofen is stronger than acetaminophen for every kind of pain.
Ibuprofen + acetaminophen: different mechanisms can produce additive analgesia
A Cochrane review of acute postoperative pain (3 trials, 1647 participants) found that a fixed-dose ibuprofen + acetaminophen combination after wisdom-tooth extraction could provide good pain relief over 6 hours to more people than the same dose of ibuprofen alone, while reducing rescue medication use.
This shows that combining different pathways and stacking NSAIDs of the same class are entirely different things. Medical instructions and total-dose limits still apply.
Loxoprofen vs ibuprofen: the same class, but unequal amounts of modern evidence
In active-comparator trials summarized by a 2016 loxoprofen review, oral loxoprofen generally did not differ significantly from ibuprofen in analgesic efficacy for conditions such as knee OA. Results were also similar to comparators including naproxen and celecoxib.
Limitations: Direct comparative studies of loxoprofen are fewer, older and geographically concentrated. They do not justify claiming that loxoprofen is stronger or safer than ibuprofen.
Fever / viral upper respiratory infection: symptom relief ≠ a shorter illness
Both NSAIDs and acetaminophen can reduce fever and pain, but this is symptomatic treatment. A loxoprofen placebo-controlled URTI study did not show a clear reduction in illness duration.
Feeling better after taking a medicine must therefore be distinguished from curing the disease or shortening its course.
Walk through the whole process with one example: pain after tooth extraction
6. Organ toxicity: what requires a deeper understanding
6.1 Gastrointestinal tract: systemic NSAID injury matters more than local irritation
Loxoprofen / Ibuprofen：Inhibition of gastric mucosal PGE₂/PGI₂ reduces mucosal blood flow, mucus and bicarbonate defenses. Together with local drug irritation, this can cause dyspepsia, erosion, ulcers, bleeding and perforation.
Older age, a history of ulcers, anticoagulants / antiplatelets, systemic steroids, SSRIs and alcohol can increase GI bleeding risk.
Acetaminophen：does not cause the same degree of peripheral COX-mediated gastropathy and is therefore not a typical NSAID ulcer-causing medicine. This does not mean zero GI adverse effects or zero bleeding risk; situations such as warfarin coadministration still need separate assessment.
6.2 Kidneys: the NSAID triple whammy is a hemodynamic problem
A recent systematic review/meta-analysis (5 case-control studies, 410,130 people) associated triple-whammy exposure with increased AKI risk. The AKI pooled analysis included 4 of those studies: OR approximately 2.01, 95% CI 1.30–3.10. Heterogeneity was high and certainty low; these numbers indicate the direction of risk, not an individual prediction.
6.3 Cardiovascular system / blood pressure / fluids
NSAID inhibition of renal prostaglandins can cause Na⁺ / H₂O retention, increased blood pressure, edema and destabilization of heart failure; the prostacyclin / thromboxane balance also affects thrombotic risk. Current Japanese loxoprofen and ibuprofen labeling both warn of serious adverse reactions such as myocardial infarction and cerebrovascular events.
Quantitative evidence requires great care: The large CNT meta-analysis found increased risks of major coronary events, heart failure and upper GI complications with high-dose, long-term ibuprofen, mostly around 2400 mg/day in RA/OA populations. These figures cannot be directly extrapolated to occasional OTC use of 200–400 mg, but they support dose- and duration-dependent NSAID class risk.
6.4 Acetaminophen hepatotoxicity: NAPQI is central
At routine therapeutic doses, most acetaminophen undergoes glucuronidation / sulfation. A small fraction forms NAPQI through CYP and is normally detoxified by glutathione. In overdose or with a reduced safety margin, NAPQI accumulation can cause centrilobular hepatic necrosis.
6.5 Typical pharmacological and risk profiles (qualitative comparison)
| Aspect | Loxoprofen | Ibuprofen | Acetaminophen |
|---|---|---|---|
| Anti-inflammatory action | Has NSAID anti-inflammatory activity | Has NSAID anti-inflammatory activity | Weak peripheral anti-inflammatory activity |
| Typical GI ulcers | COX inhibition reduces gastric mucosal defense | COX inhibition reduces gastric mucosal defense | No equivalent typical NSAID ulcer mechanism; risk is still not zero |
| Hemodynamic AKI | Renal prostaglandin inhibition is an important risk mechanism | Renal prostaglandin inhibition is an important risk mechanism | Not the same typical mechanism, but kidney injury is still possible |
| Dose-related liver toxicity | Can also cause liver injury, not primarily through NAPQI | Can also cause liver injury, not primarily through NAPQI | NAPQI / GSH depletion is central to overdose toxicity |
This table cannot calculate an individual’s risk. NSAIDs can also cause liver injury and acetaminophen can also cause kidney injury; their typical mechanisms and dominant risks differ.
7. Drug–drug interactions: the combinations most worth remembering
| Concomitant medicine / condition | Loxoprofen | Ibuprofen | Acetaminophen | Medical mechanism |
|---|---|---|---|---|
| Another NSAID | Avoid combining on your own | Avoid combining on your own | Not the same class, but the prescribed regimen still applies | NSAID + NSAID usually increases GI, renal and bleeding toxicity without necessarily increasing analgesia proportionately |
| Low-dose aspirin | Also a COX medicine; requires medical assessment | May interfere with aspirin’s antiplatelet effect; timing matters | No typical ibuprofen–aspirin COX-1 competition | Ibuprofen can temporarily occupy platelet COX-1, affecting aspirin’s irreversible acetylation |
| Warfarin / anticoagulant | bleeding risk ↑ | bleeding risk ↑ | Repeated use may increase warfarin effect / INR | NSAIDs: platelets + GI mucosa; APAP: a more complex warfarin interaction mechanism |
| ACEi / ARB + diuretic | AKI risk ↑ | AKI risk ↑ | No typical triple-whammy COX hemodynamic effect | afferent constriction + efferent dilation + hypovolemia |
| Lithium | Concentration may increase | Concentration may increase | Not a typical central interaction | NSAIDs reduce renal lithium clearance |
| Methotrexate | Toxicity may increase | Toxicity may increase | Not a major class interaction | Renal clearance / protein binding, etc. |
| SSRI / corticosteroid | GI bleed risk ↑ | GI bleed risk ↑ | No equivalent NSAID GI mechanism | Multiple hemostatic / mucosal risks combine |
| Long-term heavy alcohol use | GI and other risks require attention | GI and other risks require attention | Reduced hepatotoxicity safety margin | CYP2E1 / glutathione, nutritional status and other factors |
| Other acetaminophen-containing products | Different ingredient | Different ingredient | The most common route to accidental overdose | Different brand names but the same active ingredient; total doses add up |
8. Special populations: the same medicine can carry very different risks
Expand a scenario to see the mechanisms and risks of the three medicines. This is not a tool for individual prescribing decisions.
Ulcers / GI bleeding
Ulcers / GI bleeding: Loxoprofen and ibuprofen both cause typical NSAID gastropathy, and active peptic ulcer is a contraindication in Japanese labeling. Loxoprofen’s prodrug design does not eliminate systemic COX inhibition. Acetaminophen lacks the same NSAID ulcer mechanism, but combinations such as warfarin still require individual assessment.
CKD / dehydration
CKD / dehydration: Loxoprofen and ibuprofen reduce renal prostaglandins, constricting the afferent arteriole. AKI risk becomes especially important with volume depletion, CKD, HF, older age or ACEi/ARB + diuretics. Acetaminophen lacks the same typical hemodynamic mechanism, but is not free of renal risk.
Hypertension / HF / CV
Hypertension / HF / CV: NSAIDs can cause Na/H₂O retention, increased BP, edema and HF destabilization, and carry warnings for thrombotic events. High-dose, long-term ibuprofen has a safety signal in large meta-analyses. Comparative outcome data for loxoprofen are fewer; less data must not be interpreted as greater safety.
Liver disease / heavy alcohol use
Liver disease / heavy alcohol use: Acetaminophen particularly requires attention to total dose, duplicate products, nutrition and the NAPQI/GSH balance. Severe liver dysfunction is a contraindication in Japanese Calonal labeling. NSAIDs can also rarely cause hepatic injury, but not through the same dose-dependent NAPQI toxicology.
Pregnancy
Pregnancy: Loxoprofen and ibuprofen are contraindicated in late pregnancy in Japan. The FDA recommends avoiding NSAIDs from around 20 weeks unless clinically necessary. Acetaminophen is often a main alternative when pain or fever relief is needed, but still requires the lowest effective dose for the shortest necessary time and assessment by obstetric or other medical professionals.
Aspirin asthma / AERD
Aspirin asthma / AERD： COX-1 inhibition by loxoprofen and ibuprofen can trigger bronchospasm, so Japanese labeling contraindicates use in aspirin asthma or a history of it. Acetaminophen is not a typical NSAID, but highly sensitive people may still react; it cannot be called absolutely safe.
Older adults
Older adults: Reduced renal reserve and GI mucosal defense, HF / hypertension, polypharmacy and anticoagulant use all make NSAID adverse events more likely. Acetaminophen often avoids some NSAID class risks, but liver function, nutrition, total dose and duplicate ingredients still matter.
AERD / aspirin asthma: why can NSAIDs trigger asthma?
In aspirin-exacerbated respiratory disease, strong COX-1 inhibition shifts the arachidonic-acid mediator balance toward cysteinyl leukotrienes, causing bronchoconstriction and upper-airway inflammation. Japanese loxoprofen and ibuprofen labeling both contraindicate aspirin asthma or a history of it.
Acetaminophen is not a typical NSAID, but highly sensitive people may still react. It must not be interpreted as absolutely safe for every patient with NSAID-induced asthma.
Pregnancy: timing matters more than whether a medicine is usually safe
NSAIDs：Current Japanese loxoprofen / ibuprofen labeling contraindicates late pregnancy. The FDA also recommends avoiding NSAIDs from around 20 weeks unless clinically necessary, because fetal renal dysfunction can lead to oligohydramnios; after around 30 weeks there is also a risk of premature closure of the ductus arteriosus.
Acetaminophen：is still often regarded by obstetric organizations as a main option when an analgesic / antipyretic is needed during pregnancy, but it should be used at the lowest effective dose for the shortest necessary duration, in consultation with a medical professional. Current Japanese Calonal labeling likewise requires a benefit–risk assessment.
9. Toxicology: overdose is not the same condition for all three
Loxoprofen
Primarily approached as NSAID overdose / toxicity: GI, renal, CNS, acid–base and hemodynamic problems. Structured human overdose data are far more limited than for ibuprofen / acetaminophen.
Seek medical assessment directly if a large accidental ingestion is suspected. Safety in overdose cannot be inferred from tolerating the usual dose.
Ibuprofen
Larger overdoses can cause nausea/vomiting, CNS depression, AKI, metabolic acidosis and hypotension. Management is mainly supportive and guided by severity.
A short half-life does not mean an overdose can be watched at home.
Acetaminophen
A time-sensitive hepatotoxic emergency. Clinicians assess risk using ingestion timing, serum acetaminophen levels and other information. N-acetylcysteine (NAC) is the key antidote.
Early symptoms can be mild. Feeling well now does not rule out serious hepatotoxicity.
10. Clinical interpretation: ask what kind of pain and what kind of risk, rather than which is strongest
| Clinical phenotype | Pharmacological assessment | The trade-off that matters |
|---|---|---|
| Dental pain / extraction / sprain / inflammatory musculoskeletal pain | The NSAID pathway is particularly relevant: reduced peripheral PGE₂ sensitization | Ibuprofen has strong direct RCT evidence. Loxoprofen is in the same class and has Japanese indications, but less comparative evidence |
| Fever / general headache / cold-related pain | Both NSAIDs and acetaminophen can control symptoms | Is anti-inflammatory action actually needed? Are dehydration, kidney, stomach or liver disease, alcohol or duplicate ingredients present? |
| CKD / dehydration / HF | The renal hemodynamic effect of NSAIDs may dominate the risk | Risk may matter more than a little extra anti-inflammatory action |
| Active gastric ulcer / high GI bleeding risk | Pronounced NSAID class effect | Do not mistake loxoprofen’s prodrug property for absence of ulcer risk |
| Liver disease / malnutrition / chronic heavy alcohol use | The therapeutic margin of acetaminophen requires greater caution | Total acetaminophen exposure, nutrition and CYP/GSH status |
| Need for aspirin antiplatelet therapy | Ibuprofen presents a clear pharmacodynamic interference concern | Do not guess a dosing interval yourself; have a doctor or pharmacist arrange it |
11. A more precise conclusion about strength
Reasonable statements
- In the highly inflammatory acute dental pain model, a single dose of ibuprofen 400 mg is more effective than acetaminophen 1000 mg, supported by high-quality Cochrane evidence.
- Loxoprofen 60 mg and common therapeutic doses of ibuprofen occupy the same NSAID clinical tier. Existing active-comparator studies have not shown consistent superiority of loxoprofen over ibuprofen.
- Acetaminophen’s advantage is its different adverse-effect profile, not strong anti-inflammatory action.
Statements that are not justified
- 「60 mg loxoprofen = 200 mg ibuprofen = 500 mg acetaminophen」。
- “Loxoprofen is a prodrug, so it must be gentler on the stomach than ibuprofen.”
- “Acetaminophen has absolutely no risk to the kidneys or stomach.”
- “Ibuprofen has the most global research, so it must be the best choice for everyone.”
- “Stacking loxoprofen + ibuprofen makes the treatment stronger.”
12. Quick medicine reference: expand the clinical fingerprint
Expand a medicine to see its clinical fingerprint.
Loxoprofen
Loxoprofen clinical fingerprint：Reasonable when peripheral anti-inflammatory action is needed; 60 mg is a common single adult dose in Japan. Its defining feature is prodrug → active trans-OH. Do not mistake the prodrug for gastric or renal protection. The main risks remain those of the NSAID class: GI ulcer/bleeding, AKI, fluid retention/HF, AERD and drug interactions. Its evidence base is smaller than ibuprofen’s.
Ibuprofen
Ibuprofen clinical fingerprint：A typical nonselective NSAID with extensive worldwide research. It has strong direct evidence for acute inflammatory dental pain. In the R/S racemate, the S-enantiomer is mainly responsible for COX inhibition. Particularly remember GI/renal/CV class risks and pharmacodynamic interference with low-dose aspirin.
Acetaminophen
Acetaminophen clinical fingerprint：Mainly analgesia + antipyresis, rather than strong peripheral anti-inflammatory activity. Its advantage is avoiding typical NSAID COX-mediated GI, renal and platelet physiology; the trade-off is dose-dependent hepatic toxicity. The greatest practical pitfall is duplicate acetaminophen across different brands.
13. Evidence hierarchy & limitations
Official labeling Answers questions about approved indications, dose ranges, contraindications, interactions and serious adverse reactions. It is not a comparative-effectiveness ranking.
Answers questions about efficacy and safety for a particular disease, dose and outcome. It cannot be freely extrapolated to different doses or populations.
Mechanistic study Explains why, for example through the active metabolite of loxoprofen, ibuprofen stereochemistry or NAPQI. Clinical superiority cannot be inferred from in vitro IC₅₀ alone.
The largest information gap: The global evidence base for ibuprofen is much larger than for loxoprofen. For loxoprofen’s long-term cardiovascular and comparative safety, a lack of large outcome trials must not be interpreted as greater safety.
14. Main sources (official information prioritized)
Randomized, double-blind, placebo-controlled trial · PMID 17675766
https://www.pmda.go.jp/PmdaSearch/rdDetail/iyaku/1149019F1579_1?user=1
Current product page / package insert dated 2025-07-22.
https://www.pmda.go.jp/PmdaSearch/rdDetail/iyaku/1149001D1160_1?user=1
Official Japanese prescription ibuprofen labeling.
https://www.pmda.go.jp/PmdaSearch/rdDetail/iyaku/1141007F1063_5?user=1
Current package insert dated 2026-08-25.
DailyMed current label
Cochrane CD004624
Cochrane CD010210
PubMed PMID 27444038
PubMed PMID 11771573
PMC3778977
Mostly high-dose, longer-term NSAID trials; not directly applicable to occasional OTC use.
PMC12569550
FDA Drug Safety Communication
ACOG Practice Advisory
Static content does not depend on external resources; external links require a network connection. The page reflects information available as of 2026-09-30.